FAQ: Datavault AI's Exclusive License to Scilex for AI-Driven Biotech Exchange Platform
TL;DR
Datavault AI grants Scilex exclusive biotech license, creating a $2 trillion market opportunity for non-dilutive funding through asset tokenization.
Datavault AI's proprietary technology enables Scilex to build a Biotech Exchange platform for tokenizing, trading, and monetizing genomic data and drug information.
This partnership advances biotech innovation by enabling secure data sharing and funding access, potentially accelerating medical breakthroughs and treatments.
Datavault AI's deal includes a $10 million upfront payment and up to $2.55 billion in milestones for blockchain-based biotech asset tokenization.
Found this article helpful?
Share it with your network and spread the knowledge!
Datavault AI has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology for building and operating a Biotech Exchange platform in the biotech and biopharma sectors.
Scilex is licensing Datavault AI's proprietary AI-driven technology that enables tokenization, trading, and monetization of biotech assets such as genomic data, diagnostics, and drug information.
The deal includes a $10 million upfront payment in four installments and up to $2.55 billion in potential milestone payments.
The technology is expected to expand into a Pharmaceutical Exchange platform addressing an estimated $2 trillion market opportunity, providing companies with access to non-dilutive funding.
The platform will tokenize, trade, and monetize biotech assets including genomic data, diagnostics, and drug information.
Datavault AI specializes in AI-driven blockchain solutions for data monetization and asset tokenization, with divisions focused on Acoustic Science and Data Science technologies.
The latest news and updates relating to DVLT are available in the company's newsroom at https://ibn.fm/DVLT, and more information about the company can be found at www.datavaultsite.com.
Scilex has been granted an exclusive worldwide license, meaning they have exclusive rights to deploy this technology globally.
Datavault AI brings its broad patent portfolio and proven high-performance computing expertise to support this licensing agreement.
Datavault AI expects the technology to expand into a Pharmaceutical Exchange platform, creating additional opportunities in the broader pharmaceutical market.
Curated from InvestorBrandNetwork (IBN)
